Further market studies were conducted to identify, and solve eventually challenges in the market introduction of the RBM-Screen device, hereunder market up-take issues, unique selling points and strategic partnerships.
Result of interviewed physicians pointed out, that the pressure on hospital budgets and the increasing cost per bed day forces the hospitals to find new ways of avoiding hospitalization, by supporting self-treatment, self-monitoring, empowerment and therefore reliable devises placed on patient location in close cooperation primary with practitioners and secondary with hospitals.
The result of interviews with former patients pointed out the need to reduce false alarms and herewith reduce fear and uncertainty. Today former patients often have direct contact with hospitals and get by symptoms hospitalized, even if it’s known that a large number of hospitalization of former patients (according to interview) are false alarms.
In exploring alternative spectroscopic method for optimal device design many experiments were performed in collaboration with Danish Technological Institute (DTI). There is good evidence to make a RBM-Screen device with fast and low detection level, when comparing to physiological concentrations of the pure compounds in aqueous solution using our spectroscopy method.
A thought-out development plan towards the final RBM-screen device was conducted, including identification and establishment of partnership with component manufacturers, clarifying ISO certification issues and IP management.
This development plan was hereafter described in several WPs, which has to be done in the innovation project hereafter, including description of tests and observation studies on different locations under existing work flow conditions with patient’s involvement, prototyping processes, user interface requirements, tests for reliability, prediction of cost and time saving impacts and infrastructure for information flow.
